Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine
作者:Abdelouahid Samadi、Cristóbal de los Ríos、Irene Bolea、Mourad Chioua、Isabel Iriepa、Ignacio Moraleda、Manuela Bartolini、Vincenza Andrisano、Enrique Gálvez、Carolina Valderas、Mercedes Unzeta、José Marco-Contelles
DOI:10.1016/j.ejmech.2012.03.022
日期:2012.6
(IC50 = 31 ± 2 nM) and a moderately selective eqBuChE inhibitor (IC50 = 4.7 ± 0.2 μM). Conversely, the new and readily available 5-amino-7-(prop-2-yn-1-yl)-6,7,8,9-tetrahydropyrido[2,3-b][1,6]naphthyridine derivatives 9–13 of type II are poor MAO inhibitors, but showed AChE selective inhibition, compound 12 being the most attractive as it acts as a non-competitive inhibitor on EeAChE (IC50 = 25 ± 3 nM, Ki = 65 nM)
合成,药理学评估和分子建模杂环取代的烷基和环烷基炔丙基胺1 - 7型的我,和9 - 12型的II,设计为多能的抑制剂能够同时抑制单胺氧化酶(MAO-A / B),以及描述了作为胆碱酯酶(AChE / BuChE)的酶,作为治疗阿尔茨海默氏病的潜在药物。吲哚衍生物1 - 7型的我是公知的MAO抑制剂,其容量,以抑制乙酰胆碱酯酶和丁酰胆碱酯酶在这里研究首次。结果,化合物7被鉴定为MAO-B抑制剂(IC 50 = 31±2 nM)和中等选择性eqBuChE抑制剂(IC 50 = 4.7±0.2μM)。相反,新的和容易获得的5-氨基-7-(prop-2-yn-1-yl)-6,7,8,9-四氢吡啶并[2,3- b ] [1,6]萘啶衍生物9 – II型中的13种是较弱的MAO抑制剂,但表现出AChE选择性抑制作用,化合物12最有吸引力,因为它作为Ee AChE的非竞争性抑制剂起作用(IC 50 =